Behçet's disease: new insight into the relationship between procoagulant state, endothelial activation/damage and disease activity

Ihosvany Fernández-Bello, Francisco J López-Longo, Elena G Arias-Salgado, Víctor Jiménez-Yuste, Nora V Butta, Ihosvany Fernández-Bello, Francisco J López-Longo, Elena G Arias-Salgado, Víctor Jiménez-Yuste, Nora V Butta

Abstract

Background: Behçet disease (BD) is associated with a prothrombotic state of unknown origin that may lead to life-threatening events. Calibrated Automated Thrombogram (CAT) and Rotational Thromboelastometry (ROTEM) are two global haemostasis assays that may reveal new insights into the physiopathological mechanisms of the disease and its procoagulant condition.

Methods: 23 BD patients who had no signs or symptoms of current thrombosis and 33 age- and sex-matched controls were included in the study. We performed ROTEM and CAT tests and assessed erythrocyte count, platelet count, platelet contribution to clot formation and plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor type 1 (PAI-1), fibrinogen, C-reactive protein (CRP), thrombin-antithrombin III complex (TAT), D-dimer and E-selectin (ES).

Results: Both ROTEM and CAT tests showed a hypercoagulable state in the BD patients. Plasma levels of PAI-1, fibrinogen, TAT, CRP and ES were significantly increased in this group compared to controls. The disease activity (DA) was significantly correlated with levels of ES and the maximum clot firmness, and this last one, in turn, correlated with rising levels of ES, PAI-1, CRP and fibrinogen. CAT parameters did not correlate with DA or ES.

Conclusions: Both ROTEM and CAT tests reveal that patients with BD have a procoagulant state even in the absence of thrombosis. ROTEM test indicates that increased levels of fibrinogen and PAI-1 may be involved in the prothrombotic state of this pathology, while platelets do not significantly contribute. Moreover, CAT assay demonstrate that plasma from BD patients is able to generate more thrombin than controls in response to the same stimulus and that this effect is independent of the DA and the endothelial impairment suggesting the involvement of another factor in the hypercoagulable state observed in BD patients. This study also shows that endothelium activation/damage may be a contributing factor in both the procoagulant and clinical conditions of BD, as shown by the direct correlation between ES levels, ROTEM parameters and DA.

Figures

Figure 1
Figure 1
Correlation between disease activity (DA) and INTEM-MCF, INTEM-α and soluble E-selectin (ES).
Figure 2
Figure 2
Correlation between soluble E-selectin (ES) and INTEM-CFT, INTEM-MCF and INTEM-α.

References

    1. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med. 1999;341:1284–1291. doi: 10.1056/NEJM199910213411707.
    1. Koc Y, Gullu I, Akpek G, Akpolat T, Kansu E, Kiraz S, Batman F, Kansu T, Balkanci F, Akkaya S. Vascular involvement in Behcet's disease. J Rheumatol. 1992;19:402–410.
    1. Davatchi F, Assaad-Khalil S, Calamia KT, Crook JE, Sadeghi-Abdollahi B, Schirmer M, Tzellos T, Zouboulis CC, Akhlagi M, International Team for the Revision of the International Criteria for Behcet's D. The International Criteria for Behcet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2013.
    1. Altenburg A, Mahr A, Maldini C, Kneifel CE, Krause L, Kotter I, Stache T, Bonitsis NG, Zouboulis CC. Epidemiology and clinical aspects of Adamantiades-Behcet disease in Gemany. Current data. Der Ophthalmologe. 2012;109:531–541. doi: 10.1007/s00347-012-2601-4.
    1. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease. Lancet. 1990;335:1078–1080.
    1. Haznedaroglu IC, Ozcebe OI, Ozdemir O, Celik I, Dundar SV, Kirazli S. Impaired haemostatic kinetics and endothelial function in Behcet's disease. J Intern Med. 1996;240:181–187. doi: 10.1046/j.1365-2796.1996.396853000.x.
    1. Chambers JC, Haskard DO, Kooner JS. Vascular endothelial function and oxidative stress mechanisms in patients with Behcet's syndrome. J Am Coll Cardiol. 2001;37:517–520. doi: 10.1016/S0735-1097(00)01137-2.
    1. Espinosa G, Font J, Tassies D, Vidaller A, Deulofeu R, Lopez-Soto A, Cervera R, Ordinas A, Ingelmo M, Reverter JC. Vascular involvement in Behcet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin. Am J Med. 2002;112:37–43. doi: 10.1016/S0002-9343(01)01048-8.
    1. Aitchison R, Chu P, Cater DR, Harris RJ, Powell RJ. Defective fibrinolysis in Behcet's syndrome: significance and possible mechanisms. Ann Rheum Dis. 1989;48:590–593. doi: 10.1136/ard.48.7.590.
    1. Ricart JM, Ramon LA, Vaya A, Espana F, Santaolaria ML, Todoli J, Castello R, Fontcuberta J, Estelles A. Fibrinolytic inhibitor levels and polymorphisms in Behcet disease and their association with thrombosis. Br J Haematol. 2008;141:716–719. doi: 10.1111/j.1365-2141.2008.07078.x.
    1. Yurdakul S, Hekim N, Soysal T, Fresko I, Bavunoglu I, Ozbakir F, Tabak F, Melikoglu M, Hamuryudan V, Yazici H. Fibrinolytic activity and d-dimer levels in Behcet's syndrome. Clin Exp Rheumatol. 2005;23:S53–S58.
    1. Wilson AP, Efthimiou J, Betteridge DJ. Decreased prostacyclin sensitivity of platelets in patients with Behcet's syndrome. Eur J Clin Invest. 1988;18:410–414. doi: 10.1111/j.1365-2362.1988.tb01032.x.
    1. Akar S, Ozcan MA, Ates H, Gurler O, Alacacioglu I, Ozsan GH, Akkoc N, Ozkan S, Demirkan F, Onen F. Circulated activated platelets and increased platelet reactivity in patients with Behcet's disease. Clin Appl Thromb/Hemost. 2006;12:451–457. doi: 10.1177/1076029606293430.
    1. Hemker HC, Giesen P, Al Dieri R, Regnault V, de Smedt E, Wagenvoord R, Lecompte T, Beguin S. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33:4–15. doi: 10.1159/000071636.
    1. Luddington RJ. Thrombelastography/thromboelastometry. Clin Lab Haematol. 2005;27:81–90. doi: 10.1111/j.1365-2257.2005.00681.x.
    1. van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol. 2008;142:889–903. doi: 10.1111/j.1365-2141.2008.07267.x.
    1. Ten Cate H. Thrombin generation in clinical conditions. Thromb Res. 2012;129:367–370. doi: 10.1016/j.thromres.2011.10.017.
    1. Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Behcet's disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford) 1999;38:728–733. doi: 10.1093/rheumatology/38.8.728.
    1. Hampton KK, Chamberlain MA, Menon DK, Davies JA. Coagulation and fibrinolytic activity in Behcet's disease. Thromb Haemost. 1991;66:292–294.
    1. Lee YJ, Kang SW, Yang JI, Choi YM, Sheen D, Lee EB, Choi SW, Song YW. Coagulation parameters and plasma total homocysteine levels in Behcet's disease. Thromb Res. 2002;106:19–24. doi: 10.1016/S0049-3848(02)00085-3.
    1. Probst K, Fijnheer R, Rothova A. Endothelial cell activation and hypercoagulability in ocular Behcet's disease. Am J Ophthalmol. 2004;137:850–857. doi: 10.1016/j.ajo.2003.12.010.
    1. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology (Baltimore, Md) 1990;12:1179–1186. doi: 10.1002/hep.1840120517.
    1. Lang T, Johanning K, Metzler H, Piepenbrock S, Solomon C, Rahe-Meyer N, Tanaka KA. The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia. Anesth Analg. 2009;108:751–758. doi: 10.1213/ane.0b013e3181966675.
    1. Jacquemin B, Antoniades C, Nyberg F, Plana E, Muller M, Greven S, Salomaa V, Sunyer J, Bellander T, Chalamandaris AG. Common genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains affect fibrinogen levels and the response to proinflammatory stimulation in myocardial infarction survivors: the AIRGENE study. J Am Coll Cardiol. 2008;52:941–952. doi: 10.1016/j.jacc.2008.06.016.
    1. Dielis AW, Castoldi E, Spronk HM, van Oerle R, Hamulyak K, Ten Cate H, Rosing J. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost. 2008;6:125–131.
    1. Lovely RS, Boshkov LK, Marzec UM, Hanson SR, Farrell DH. Fibrinogen gamma' chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. Br J Haematol. 2007;139:494–503. doi: 10.1111/j.1365-2141.2007.06825.x.
    1. Mosesson MW. Update on antithrombin I (fibrin) Thromb Haemost. 2007;98:105–108.
    1. Hemker HC, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006;96:553–561.
    1. Regnault V, Beguin S, Wahl D, de Maistre E, Coenraad Hemker H, Lecompte T. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost. 2003;89:208–212.
    1. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86:385–391. doi: 10.1172/JCI114723.
    1. Bowbrick VA, Mikhailidis DP, Stansby G. Influence of platelet count and activity on thromboelastography parameters. Platelets. 2003;14:219–224. doi: 10.1080/0953710031000118849.
    1. Martinez M, Ricart JM, Ruiz-Aja S, Rus A, Todoli J, Calvo J, Vaya A. Platelet activation and red blood cell phosphatidylserine exposure evaluated by flow cytometry in patients with Behcet's disease: are they related to thrombotic events? Pathophysiol Haemost Thromb. 2007;36:18–22. doi: 10.1159/000112635.
    1. Fernandez Bello I, Alvarez MT, Lopez-Longo FJ, Arias-Salgado EG, Martin M, Jimenez-Yuste V, Rodriguez de la Rua A, Butta NV. Platelet soluble CD40L and matrix metalloproteinase 9 activity are proinflammatory mediators in Behcet disease patients. Thromb Haemost. 2012;107:88–98.
    1. Spiezia L, Radu C, Marchioro P, Bertini D, Rossetto V, Castelli M, Pagnan A, Sorensen B, Simioni P. Peculiar whole blood rotation thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients. Thromb Haemost. 2008;100:1106–1110.
    1. Carmeliet P, Collen D. Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis. Curr Opin Lipidol. 1997;8:118–125. doi: 10.1097/00041433-199704000-00010.
    1. Demirer S, Sengul N, Yerdel MA, Tuzuner A, Ulus AT, Gurler A, Bergqvist D, Siegbahn A, Karacagil S. Haemostasis in patients with Behcet's disease. Eur J Vasc Endovasc Surg. 2000;19:570–574. doi: 10.1053/ejvs.2000.1091.
    1. Ozoran K, Dugun N, Gurler A, Tutkak H, Tokgoz G. Plasma von Willebrand factor, tissue plasminogen activator, plasminogen activator inhibitor, and antithrombin III levels in Behcet's disease. Scand J Rheumatol. 1995;24:376–382. doi: 10.3109/03009749509095184.
    1. Shang H, Ye JJ, Ji M, Wang FF, Zhu YY, Qi XM. Anticoagulant and Fibrinolytic Disorders in Patients with Behcet's Disease and Recurrent Aphthous Ulcer. Chin J Physiol. 2011;54:235–240.
    1. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost. 2003;1:1575–1579. doi: 10.1046/j.1538-7836.2003.00279.x.
    1. Pircher J, Merkle M, Wornle M, Ribeiro A, Czermak T, Stampnik Y, Mannell H, Niemeyer M, Vielhauer V, Krotz F. Prothrombotic effects of tumor necrosis factor alpha in vivo are amplified by the absence of TNF-alpha receptor subtype 1 and require TNF-alpha receptor subtype 2. Arthritis Res Ther. 2012;14:R225. doi: 10.1186/ar4064.
    1. Brogren H, Karlsson L, Andersson M, Wang L, Erlinge D, Jern S. Platelets synthesize large amounts of active plasminogen activator inhibitor 1. Blood. 2004;104:3943–3948. doi: 10.1182/blood-2004-04-1439.
    1. Nylander M, Osman A, Ramstrom S, Aklint E, Larsson A, Lindahl TL. The role of thrombin receptors PAR1 and PAR4 for PAI-1 storage, synthesis and secretion by human platelets. Thromb Res. 2012;129:e51–e58. doi: 10.1016/j.thromres.2011.12.021.
    1. Wang J, Li J, Liu Q. Association between platelet activation and fibrinolysis in acute stroke patients. Neurosci Lett. 2005;384:305–309. doi: 10.1016/j.neulet.2005.04.090.
    1. Pihusch V, Pihusch M, Penovici M, Kolb HJ, Hiller E, Pihusch R. Transforming growth factor beta-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoetic stem cell transplantation. Thromb Res. 2005;116:233–240. doi: 10.1016/j.thromres.2004.12.010.
    1. Fujii S, Hopkins WE, Sobel BE. Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis. Circulation. 1991;83:645–651. doi: 10.1161/01.CIR.83.2.645.
    1. Slivka SR, Loskutoff DJ. Platelets stimulate endothelial cells to synthesize type 1 plasminogen activator inhibitor. Evaluation of the role of transforming growth factor beta. Blood. 1991;77:1013–1019.
    1. Jankun J, Aleem AM, Struniawski R, Lysiak-Szydlowska W, Selman SH, Skrzypczak-Jankun E. Accelerated thrombus lysis in the blood of plasminogen activator inhibitor deficient mice is inhibited by PAI-1 with a very long half-life. Pharmacol Rep. 2009;61:673–680.
    1. Kupesiz A, Rajpurkar M, Warrier I, Hollon W, Tosun O, Lusher J, Chitlur M. Tissue plasminogen activator induced fibrinolysis: standardization of method using thromboelastography. Blood Coagul Fibrinolysis. 2010;21:320–324. doi: 10.1097/MBC.0b013e32833464e9.
    1. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost. 2005;3:1894–1904. doi: 10.1111/j.1538-7836.2005.01365.x.
    1. Chajek T, Fainaru M. Behcet's disease with decreased fibrinolysis and superior vena caval occlusion. Br Med J. 1973;1:782–783. doi: 10.1136/bmj.1.5856.782.
    1. Cunliffe WJ, Roberts BE, Dodman B. Behcet's syndrome and oral fibrinolytic therapy. Br Med J. 1973;2:486–487.
    1. Haznedaroglu IC, Ozcebe O, Celik I, Dundar SV, Kirazhi S. Haemostatic markers of procoagulant imbalance in Behcet's disease. Eur J Haematol. 1996;57:107–108.
    1. Tauber H, Innerhofer P, Breitkopf R, Westermann I, Beer R, El Attal R, Strasak A, Mittermayr M. Prevalence and impact of abnormal ROTEM(R) assays in severe blunt trauma: results of the 'Diagnosis and Treatment of Trauma-Induced Coagulopathy (DIA-TRE-TIC) study'. Br J Anaesth. 2011;107:378–387. doi: 10.1093/bja/aer158.
    1. Bernhard H, Deutschmann A, Leschnik B, Schweintzger S, Novak M, Hauer A, Muntean W. Thrombin generation in pediatric patients with Crohn's disease. Inflamm Bowel Dis. 2011;17:2333–2339. doi: 10.1002/ibd.21631.
    1. Hayashi T, Sakurai Y, Fukuda K, Yada K, Ogiwara K, Matsumoto T, Yoshizawa H, Takahashi Y, Yoshikawa Y, Hayata Y. Correlations between global clotting function tests, duration of operation, and postoperative chest tube drainage in pediatric cardiac surgery. Paediatr Anaesth. 2011;21:865–871. doi: 10.1111/j.1460-9592.2011.03524.x.
    1. Haznedaroglu E, Karaaslan Y, Buyukasik Y, Kosar A, Ozcebe O, Haznedaroglu C, Kirazli E, Dundar SV. Selectin adhesion molecules in Behcet's disease. Ann Rheum Dis. 2000;59:61–63. doi: 10.1136/ard.59.1.61.
    1. Tayer-Shifman OE, Seyahi E, Nowatzky J, Ben-Chetrit E. Major vessel thrombosis in Behcet's disease: the dilemma of anticoagulant therapy - the approach of rheumatologists from different countries. Clin Exp Rheumatol. 2012;30:735–740.
    1. Uzun O, Akpolat T, Erkan L. Pulmonary vasculitis in behcet disease: a cumulative analysis. Chest. 2005;127:2243–2253. doi: 10.1378/chest.127.6.2243.
    1. Kahraman OC-OS, Kamali S. Long-term course of deep venous thrombosis in patients with Behçet’s disease. Orlando, Florida New Jersey, USA: Wiley; 2003. (Proceedings of the American College of Rheumatology 67th Annual Scientific Meeting).
    1. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, Serdaroglu S, Oguz V, Yurdakul S, Lovatt GE. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990;322:281–285. doi: 10.1056/NEJM199002013220501.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi